PTPN2 and cancer: Knockout of Ptpn2 in formerly resistant cancer cells resulted in responsiveness to immunotherapy, similar to our LLC-sh21 cells silenced for Socs1. Thus, we speculate that therapies targeting the SOCS family of proteins and similar phosphatases to PTPN2 could be used in combination with immunotherapy.